Stunning presentation a necessity for all SNT SH and Potential Investor
Syntara’s pan LOX (lysyl oxidase) inhibitors caught her attention, with potential to inhibit the enzymes that create scar tissue. Research was put into clinical trials in 2023 with 42 patients volunteering to apply the topical cream to their scars in a 3-month study.The results were highly encouraging, showing 66% reduction in LOX enzyme activity which is responsible for the cross linking of collagen fibres implicated in adverse scarring. Collagen was reduced by 30%, a result Professor Wood described as “an unprecedented change to the scar composition that we have not seen with any other form of treatment.”
That’s SNT’s Principal Investigator
The Phase 1 results encouraged me to place SNT into my top 5 Holdings
Yes I am a Trader , Yes I’m here to make money ,, but I’m no where near the Sell button
Remember to like the Presentation on Youtube they all add up .NZT
Add to My Watchlist
What is My Watchlist?
